Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange in Severe COVID-19 Patients With Anti-interferon Autoantibodies
NCT05182515Phase 3Unknown
- Sponsor
- Centre Hospitalier Sainte-Anne
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Centre Hospitalier Sainte-Anne. Primary endpoint: Survival at day 28. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05182515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182515.